Buparlisib (BKM120)

For research use only.

Catalog No.S2247 Synonyms: NVP-BKM120

208 publications

Buparlisib (BKM120) Chemical Structure

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Buparlisib (BKM120) has been cited by 208 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
glioma cell lines MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zsNlczcA>? MUXJR|UxRTFvMt88US=> NEnR[489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC2OVA5OCd-MkKwOlUxQDB:L3G+
U87 MYLBdI9xfG:|aYOgRZN{[Xl? NEDVWWMz|ryP MVy3Nog> NFrKRolqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHHu[EBkdGWjdnXkJHBCWlBiYX7kJINie3Cjc3WtNy=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB4NUC4NEc,OjJyNkWwPFA9N2F-
SNU-601 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3Nog> NYDnTXVzTE2VTx?= Mme2TWM2OD1yLkixOuKyOC5yNkROwG0> NXTNO4JqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-1 M2nMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG3Nog> NYn2UodXTE2VTx?= M2i2SGlEPTB;MT6wPFLDuTBwMEK4{txO MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-668 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHCO|Jp NG[3UGRFVVOR M2WxZmlEPTB;MT61O|nDuTBwMEe0{txO MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
AGS M4P3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLq[W84Omh? M4PaeGROW09? MlTlTWM2OD1zLkexOOKyOC5zMUhOwG0> NG\RS209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-216 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTSO|Jp M3v4PGROW09? MVrJR|UxRTJwNkmyxtExNjB6Mt88US=> NHq0bpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEflZ3g4Omh? M3HJbWROW09? MYXJR|UxRTFwM{WxxtExNjB7Md88US=> M3jn[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-638 NWLlSodWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz1O|Jp NHTGR41FVVOR MnPQTWM2OD1{LkK4NuKyOC5yNUROwG0> MnvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-16 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fXTFczcA>? M{PaZWROW09? NF36V5NKSzVyPUGuOVc{yrFyLkCwNe69VQ>? MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-484 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3Nog> M3jheGROW09? NYO4SnVIUUN3ME2xMlczQMLzMD6wOFXPxE1? NF\0XY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-620 NGjPWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zS[lczcA>? M3jnTWROW09? NWnJ[IRuUUN3ME2yMlk{QcLzMD6wNFHPxE1? M4SwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-719 M{Dw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW1dmVUPzKq NX;weWpITE2VTx?= MVXJR|UxRTNwMEO3xtExNjB|Mt88US=> NUXiWVF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
MM cell lines NWTPSHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Kb3cyOM7:TR?= NV7TflBoOjSq M4X5d2ROW09? NIXDSHVKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyN{S4OUc,OjJ{MEe0PFU9N2F-
ARP-1 NIPBNnpCeG:ydH;zbZMhSXO|YYm= NF;ld3UyOM7:TR?= MlHwNlRp MljRSG1UVw>? NXz0UXhZcW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=> NHnZOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwO|Q5PSd-MkKyNFc1QDV:L3G+
colon cancer cell lines MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHlXWkxNTFyzszN MWW3Nog> MXLEUXNQ M{jKfGlEPTB;Md88US=> Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
gastric cancer cell lines MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLKNE0yOM7:TR?= M122SVczcA>? M2n3Z2ROW09? M3TxU2lEPTB;Mj21{txO NV\VPVh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
HCT-116/HT-29/MKN-45 NILmXIZCeG:ydH;zbZMhSXO|YYm= M1XyOVLPxE1? M4\6cVQ5cA>? NWrkNYd4e2irZoSgbY4hTzJicHjhd4U> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HT-29 and HCT-116 NV3SW5V4S2G|cHHz[UBie3OjeR?= NIHDV|I2|ryP M{iyTFI1cA>? MniwbY5lfWOnczDjZZNx[XOnIHHjeIl3cXS7 MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
PIK3CA-mutant MCF7 NFPUSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPES2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? M3z5UVczcA>? MorIS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? M1P5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWzPVY4Lz5{Mk[1N|k3PzxxYU6=
PIK3CA-mutant MCF7 NYi4R2FiU2mwYYPlJGF{e2G7 M13RXGlEPTB;MUG0xtE{dk1? NILwRoY4Omh? NGPXXHdKSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz NWrRUJZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
MCF7-myr-Akt NX[zSHNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M1e0NFczcA>? NH6zUWFIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= M4nTfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWzPVY4Lz5{Mk[1N|k3PzxxYU6=
Y1 cell line NHviNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHNWJgyOC5zzszNM|HPxE1? NIr5[I0zPGh? Mk\DSG1UVw>? NGrtdZJqdmirYnn0d{A3OO,:hTDj[YxtKH[rYXLpcIl1gSCrbjDNfYMuW2O2cj30doFve2[nY4Tl[EBk\Wyucx?= MkfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUK5NFQoRjJ{NkmyPVA1RC:jPh?=
human NSCLC NXv6eld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PVOFAvPS1{zszN NGTtems4Omh? M1u3U2lEPTB;Md88US=> M2G5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ixN|k{Lz5{Mke4NVM6OzxxYU6=
human NSCLC MX;LbY5ie2ViQYPzZZk> M3rrNlHPxE1? NIe5bZczPGh? MWXpcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62 MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN|k{RC:jPh?=
JVM2 NGftc4tEgXSxdH;4bYNqfHliYYPzZZk> NVLtPIluOC5{LUKw{txO MV63Nog> M2f3RWROW09? NG[3ZpdKSzVyPUCuPe69VQ>? NEK5fmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN|g3Ozl:L3G+
EHEB NHS0NJFEgXSxdH;4bYNqfHliYYPzZZk> NHi1e3kxNjJvMkFOwG0> M3nJWFczcA>? M2f4ZWROW09? Mo\6TWM2OD1yLkhOwG0> MlLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
MEC2 NX7YT5FzS3m2b4TvfIlkcXS7IHHzd4F6 NGHEdW8xNjJvMkFOwG0> NV7qNZZNPzKq NVXjfoJRTE2VTx?= NXXTVW0xUUN3ME2wMlfPxE1? NH3ES|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN|g3Ozl:L3G+
primary B-CLL lymphocytes NHvrXXlCeG:ydH;zbZMhSXO|YYm= NV;4RZBjUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= NXvzUYFROjSq NHPBNXZFVVOR MnrGTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> M3;YdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
primary B-CLL lymphocytes Ml7vT4lv[XOnIFHzd4F6 NGX0OW9KSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n M{\ZOlI1cA>? MXfpcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= M2jJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
SK-HEP1 M{\WVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[xfGIyNTJyzszN M4jt[VczcA>? NEO4eZNFVVOR MoXvTWM2OO,:nEJOwG0> MmnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN|YoRjJ|NEe5NVM3RC:jPh?=
786-0 MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLnZXEyNTJyzszN NVHqPGtxPzKq MWPEUXNQ NXLCe|lDUUN3MP-8oFHPxE1? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5OUGzOkc,OjN2N{mxN|Y9N2F-
human HCC cell lines Mn7jR4VtdCC4aXHibYxqfHliYYPzZZk> M{HlT|AvODB3LUJOwG0> M2i3S|Q5cA>? MYTJR|UxRTIQvF2= M{TQ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
Huh7 NUPXSoQzU2mwYYPlJGF{e2G7 MknXNe69VQ>? NUfC[29{PDiq NXTtXZlLe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 M3[zOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
human NSCLC cell lines NYHLRZc4SXCxcITvd4l{KEG|c3H5 NEnWWZAxNjF{NT20{txO NY[xS2loOjSq Ml\nSG1UVw>? NYrDXY1vUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> NX[3RmNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlI1PzJpPkKzOVYzPDd{PD;hQi=>
Primary CLL cells NU\2OHNmSXCxcITvd4l{KEG|c3H5 M3XVUlEuOTEQvF2= MWS0PIg> MnrPbY5lfWOnczDhdI9xfG:|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=> M3qzU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEWwPFA4Lz5{M{i1NFgxPzxxYU6=
Primary CLL cells MUfLbY5ie2ViQYPzZZk> NIS2PGcz|ryP NGGzcY8{OG2rbh?= MlvK[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NIDpUFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
Primary CLL cells Mo\ER5l1d3SxeHnjJGF{e2G7 M3TJcFLPxE1? NGjzVJczPGh? NUXv[4ROcW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> M{nRSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEWwPFA4Lz5{M{i1NFgxPzxxYU6=
LC-1/SQSF Mmm0SpVv[3Srb36gRZN{[Xl? MnXGN:69VQ>? NX7NSllXOjSq NGLmfItFVVOR NXPvbnE6\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt NH35Wmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4NFA6Oyd-MkO5PFAxQTN:L3G+
BCR-ABL M3rle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHqUWU1OC5{NT2xNO69VQ>? MXG0[C=> MmPrd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NE[xNkc,OjR{NES2NVI9N2F-
T-ALL NUDhPHg3SXCxcITvd4l{KEG|c3H5 M{\mTIJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NVTsUFVDOjRib4KgOFhp M3Wxd2ROW09? MlLTZYZn\WO2czD0bIUhWEl|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO= M2Xh[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{GwO|M3Lz5{NEOxNFc{PjxxYU6=
H1975 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnOU|JNOC5|LUmuOu69VQ>? NFrle|U4Omh? NH;IV5VFVVOR MX\JR|UxRTFwM{i1{txO MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{e4OFYoRjJ2M{O3PFQ3RC:jPh?=
H1975 M2S3[mFxd3C2b4Ppd{BCe3OjeR?= MUSy{txO Mnq0NlRp NVnkdoY3TE2VTx?= NUmwc4FEcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? NUH0Nop7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN|c5PDZpPkK0N|M4QDR4PD;hQi=>
BON NIK4OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHScYxjOS13zszN NXf3N5d4PzKq NIXUcpRl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v NHvEO3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0N|UzOyd-MkS0OFM2OjN:L3G+
BON NGH6fWxCeG:ydH;zbZMhSXO|YYm= MX[xMVXPxE1? MnjmNlRp NUT6S2p3cW6lcnXhd4V{KGGyb4D0c5Nqew>? NEDXSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0N|UzOyd-MkS0OFM2OjN:L3G+
GBM MkTIRZBweHSxc3nzJGF{e2G7 M4L3SlLPxE1? M4P3PFQ5cA>? NUPod5hYTE2VTx?= M2nmTYlv\HWlZXSgbIlocGW{IHzleoVteyCxZjDhdI9xfG:|aYOsJIFv\CCmZXPy[YF{\WRiY3XscEB3cWGkaXzpeJk> NF73Xm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwNFQ6Oid-MkS1NFA1QTJ:L3G+
FaDu MojDSpVv[3Srb36gRZN{[Xl? MlXWOUDPxE1? NH\Bbm8zPCCq NUXNUZpmTE2VTx?= MonwVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|MUG0O{c,OjR4M{GxOFc9N2F-
EMT6 MVrGeY5kfGmxbjDBd5NigQ>? M3fJc|Uh|ryP NYr1bplXOjRiaB?= MXfEUXNQ M4PYNXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NFm1PY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N|EyPDd:L3G+
HCT116 NF;yfFJHfW6ldHnvckBCe3OjeR?= M{jQ[FUh|ryP MYGyOEBp NIXGVVdFVVOR NVvPfpRpWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NX\1R4V{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|EyPDdpPkK0OlMyOTR5PD;hQi=>
U87 NWLTSlVkTnWwY4Tpc44hSXO|YYm= MVe1JO69VQ>? M2PZNlI1KGh? NEPjeXhFVVOR NHfIeo9T\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NX;mVGc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|EyPDdpPkK0OlMyOTR5PD;hQi=>
Saos-2 M{HvXWZ2dmO2aX;uJGF{e2G7 NG\CflA2OCEQvF2= MVS0PEBp NGXaVmtKdmirYnn0d{Bk\WyuIHnueoF{cW:w MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
MG-63 NWHmepl1TnWwY4Tpc44hSXO|YYm= NHfTSmU2OCEQvF2= MUO0PEBp MYDJcohq[mm2czDj[YxtKGmwdnHzbY9v MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1 M4fCdmZ2dmO2aX;uJGF{e2G7 MVW1NEDPxE1? MVK0PEBp M2rpd2lvcGmkaYTzJINmdGxiaX72ZZNqd25? Mmq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
Saos-2 MXLGeY5kfGmxbjDBd5NigQ>? NG\2ZnA2OCEQvF2= NF7LeXE1QCCq MVrJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u M2\2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
MG-63 MlzSSpVv[3Srb36gRZN{[Xl? MnvQOVAh|ryP Mn;MOFghcA>? MnLLTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> NGL2Ook9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1 Mo\2SpVv[3Srb36gRZN{[Xl? MXK1NEDPxE1? NHnoS281QCCq MlXUTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> MkDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
Saos-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm1NEDPxE1? Mn;XOFghcA>? MoX2TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63 NELIVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvUWHdmPTBizszN M2TmNFQ5KGh? M1XyN2lvcGmkaYTzJINmdGxidnnhZoltcXS7 MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKxb5U2OCEQvF2= NFPZU2I1QCCq NXHESXQ1UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
LN18 NUW4cXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VNlAh|ryP MoTpO|IhcA>? NWLqZpVlTE2VTx?= NGLHeoZKSzVyPEWg{txO NFvEfII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN229 NULhZoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKyNEDPxE1? MXy3NkBp MW\EUXNQ Ml;0TWM2ODx3IN88US=> MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO|QoRjJ2N{SxNFc1RC:jPh?=
LNZ308 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;nfIQzOCEQvF2= M1\neFczKGh? NF\hS2hFVVOR MlX3TWM2ODx3IN88US=> NHi5fZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
T98G MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTRNlAh|ryP M1TGXlczKGh? NIe3b2tFVVOR Mn;0TWM2ODx3IN88US=> NYXTXG9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O|QyODd2PD;hQi=>
U87 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTYV|ExOjBizszN MoXlO|IhcA>? M3rUXGROW09? M3;Q[WlEPTB:NTFOwG0> MnjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO|QoRjJ2N{SxNFc1RC:jPh?=
LN18 NH7zU3hHfW6ldHnvckBCe3OjeR?= NXnNc3NZPSEQvF2= M3;pcVI1KGh? MnWySG1UVw>? NIPFNo9KdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW MnLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO|QoRjJ2N{SxNFc1RC:jPh?=
LNZ308 NHfLT4hHfW6ldHnvckBCe3OjeR?= MnnyOUDPxE1? NHr5fXAzPCCq NGDUeFBFVVOR MlP4TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? M1HDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
MDA-MB-175 NUHnVVdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPFXmMzOSEQvF2= NWDDRpFbPSCm NVzVSG5JTE2VTx?= M1z2[GlEPTB:MTFOwG0> NFH3Uo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MDA-MB-134 NWKyZWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xJO69VQ>? MU[1JIQ> Ml;XSG1UVw>? NYH4XGFpUUN3MEyxJO69VQ>? NVWy[I5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1500 M1TDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjONUDPxE1? MoXiOUBl Ml:2SG1UVw>? MlHVTWM2ODxzIN88US=> NV32UIlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
EFM-19 NUjyTpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q5N|Eh|ryP MV:1JIQ> Moe5SG1UVw>? MV7JR|UxRDFizszN MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
ZR-75-30 M{\kbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQNUDPxE1? MlTROUBl M3HGfGROW09? MYDJR|UxRDFizszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-361 M{\0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BflEh|ryP M{TOeVUh\A>? MVHEUXNQ Mlz6TWM2ODxzIN88US=> M37UZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
T-47D NIjm[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HabVEh|ryP M{HDfVUh\A>? MmrnSG1UVw>? M2nTbmlEPTB:MTFOwG0> NYj0VJZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
SK-BR-3 M4\ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\jc|lEOSEQvF2= MXO1JIQ> MXLEUXNQ NHzQU3VKSzVyPEGg{txO MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
UACC-732 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXd|Eh|ryP MVm1JIQ> MXrEUXNQ MWLJR|UxRDFizszN M4C3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
BT-474 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr6NUDPxE1? NFTTPHY2KGR? MWLEUXNQ MYPJR|UxRDFizszN M2fYXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
HCC202 M3rrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrnNUDPxE1? Ml:xOUBl NU\DWopsTE2VTx?= Mnf4TWM2ODxzIN88US=> NF;QOVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MCF7 NV;Veo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHESG5SOSEQvF2= Ml7zOUBl NHy4c2VFVVOR MVfJR|UxRDFizszN NGPYdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MDA-MB-415 NY[yc4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjJOokyKM7:TR?= MUG1JIQ> M3rYOmROW09? MlTFTWM2ODxzIN88US=> MnXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
MDA-MB-453 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCwNUDPxE1? NV3mfVlYPSCm NUXLUIF4TE2VTx?= NE\RV3pKSzVyPEGg{txO M2TmZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
ZR-75-1 M2LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxJO69VQ>? MkXnOUBl M4PJNGROW09? MXnJR|UxRDFizszN NEL6Ro89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
HCC38 M1nDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJNItEOSEQvF2= M{DnUFUh\A>? MkDTSG1UVw>? MYDJR|UxRDFizszN MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1419 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS5NZBuOSEQvF2= MVu1JIQ> MoW1SG1UVw>? NESweHdKSzVyPEGg{txO MnvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
UACC-812 NGjWZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HTR|Eh|ryP NHPrPFU2KGR? MXLEUXNQ NVHYfZJMUUN3MEyxJO69VQ>? M{TJOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
HCC1187 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqNUDPxE1? M2T4OVUh\A>? NGOyd29FVVOR MVHJR|UxRDFizszN MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
KPL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxJO69VQ>? MlnrOUBl NV7QbopTTE2VTx?= MlLxTWM2ODxzIN88US=> Mn76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
SUM-225 NYXDVmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hre|Eh|ryP M4[2R|Uh\A>? NGrweZNFVVOR NXvCNIoxUUN3MEyxJO69VQ>? MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
EFM-192A NYXHengzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq2eWIyKM7:TR?= MXW1JIQ> NGPZO5ZFVVOR M{SybWlEPTB:MTFOwG0> MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
JIMT-1 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SxTVEh|ryP MUG1JIQ> MYHEUXNQ NUX6Nm0{UUN3MEyxJO69VQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1143 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSyNUDPxE1? MV61JIQ> MlXOSG1UVw>? MnTMTWM2ODxzIN88US=> NI\lVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
HCC2218 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonUNUDPxE1? NIHFSVU2KGR? MoTXSG1UVw>? M3\Fc2lEPTB:MTFOwG0> MlXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
MDA-MB-468 NEnKTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e4WlEh|ryP NF;GRmQ2KGR? MlHRSG1UVw>? NEC5cmhKSzVyPEGg{txO NU\rO2dMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-20 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xJO69VQ>? Ml;3OUBl NYjZUWNJTE2VTx?= MV\JR|UxRDFizszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-435 NIjlUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnpbGNbOSEQvF2= Ml3xOUBl M1vsdWROW09? NI[5VFZKSzVyPEGg{txO M4rhZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
BT-549 NUfzT21rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf2VpMyKM7:TR?= M1TINlUh\A>? MXzEUXNQ NFjvXWZKSzVyPEGg{txO M1f2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
HCC1806 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwNUDPxE1? NUTY[Vc4PSCm NEPjfIFFVVOR MXnJR|UxRDFizszN NUHtenV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1937 M4nxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3GcXVDOSEQvF2= NVe2c45rPSCm NWHaTo9ITE2VTx?= NGLCbHJKSzVyPEGg{txO NUL3XmNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
Hs578T NVLremFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrHOFRPOSEQvF2= NGH5e5M2KGR? MX3EUXNQ MUPJR|UxRDFizszN NYntN45lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MCF7 NVPLPZdoS3m2b4TvfIlkKEG|c3H5 MmjtO|IhcA>? M1TSRmROW09? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4PpcochWEl|S3HsdIhiKEV3NEXLJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMECxOVgh|ryP NHPsUGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
DU145 NYX6[oZIS3m2b4TvfIlkKEG|c3H5 M3zub|czKGh? NHG5dGZFVVOR NF36SFBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2= MkH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780 MXLDfZRwfG:6aXOgRZN{[Xl? MkniO|IhcA>? NYrmVnNvTE2VTx?= MlSzR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlM2KM7:TR?= NFL5ZnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
U87MG MUPDfZRwfG:6aXOgRZN{[Xl? NFXNb4s4OiCq MYrEUXNQ NFrTTIVEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3QThizszN MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
A2780 NIXJ[HhHfW6ldHnvckBCe3OjeR?= MYCxJIg> MkTBSG1UVw>? NWPST4k3UW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
DU145 NWLWRZVXTnWwY4Tpc44hSXO|YYm= NXT5PZdROSCq NXvrepF[TE2VTx?= MoXqTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? NIHENmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780 Mn7pSpVv[3Srb36gRZN{[Xl? M3XvflEhcA>? MVfEUXNQ M{XRVWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP NHywSlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
MCF7 M3nrZmZ2dmO2aX;uJGF{e2G7 NXqxZoFNOSCq MnW2SG1UVw>? M1LZcGlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? NULrZ3NLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
U87MG NFvXdGlHfW6ldHnvckBCe3OjeR?= MX2xJIg> NHjiOnRFVVOR M{[1fmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1? NEDqZ2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3roUlczKGh? NH;NcnZFVVOR MnfPSWM2OD1yLkWyJO69VQ>? NYnrZ4w2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7 NFTSfYFHfW6ldHnvckBCe3OjeR?= NHHrV4MyKM7:TR?= MUixJIg> NFnWOZdFVVOR MYjJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? NFizPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOFQxOyd-MkWwNFQ1ODN:L3G+
BNL MWXGeY5kfGmxbjDBd5NigQ>? NV\tXIJqOSEQvF2= NWHtbYVrOSCq NGrwUZlFVVOR MULJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gV|Y> NVW5SppbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFQ1ODNpPkK1NFA1PDB|PD;hQi=>
BON-1 M4\IV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\NVHl[PTByIH7N MmC4NVAh\A>? MU\EUXNQ NGf1S|VKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{NkK5Nkc,OjVyMk[yPVI9N2F-
BON-1 NVHYeYxTTnWwY4Tpc44hSXO|YYm= NV\nVWdqPTByIH7N M{\TeVQhcA>? NWTkUXRMTE2VTx?= NFfqV|BKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NGH3S3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
QGP-1 M3rNeGZ2dmO2aX;uJGF{e2G7 MlXEOVAxKG6P MVu0JIg> M4TKVGROW09? NXvS[IdQUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> NWW0bI9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
HCT-15 NUnLOWUxSXCxdH;zbZMhSXO|YYm= MXGxNEDPxE1? MU[0PEBp MVzEUXNQ M4nqZmlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xOUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NUTQRoxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
HCT-116 M2LpS2Fxd3Sxc3nzJGF{e2G7 NIq1S2EyOCEQvF2= M3rlcVQ5KGh? MmLvSG1UVw>? MoDMTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
NCI-H460 NUTub5JXSXCxdH;zbZMhSXO|YYm= M{TKOFExKM7:TR?= NXrRV4pVPDhiaB?= MoTuSG1UVw>? NWra[YRPUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> NVPMNYtzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
SKOV-3 M{OyO2Fxd3Sxc3nzJGF{e2G7 MVqxNEDPxE1? M3\KTVQ5KGh? MYHEUXNQ MmfaTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
BSY-1 NIe3eYJCeG:2b4Ppd{BCe3OjeR?= M1fXNFExKM7:TR?= NYf4ZpA5PDhiaB?= NUjico1iTE2VTx?= NHzQXW5KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
MKN-1 MVvBdI91d3OrczDBd5NigQ>? NX\5dpdFOTBizszN Ml3UOFghcA>? NV\v[FJzTE2VTx?= M2T1Smlv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
NCI-H522 MUnBdI91d3OrczDBd5NigQ>? NWDMWXU3OTBizszN Mo\KOFghcA>? MV3EUXNQ NWrCSVN1UW6mdXPld{BieG:ydH;zbZM> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
OVCAR-3 NHjNPGhCeG:2b4Ppd{BCe3OjeR?= MljSNVAh|ryP Ml:0OFghcA>? MWXEUXNQ M{PwR2lv\HWlZYOgZZBweHSxc3nz MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
HBC-5 NHntNotCeG:2b4Ppd{BCe3OjeR?= NUXlWoN6OTBizszN NGfIeVA1QCCq MW\EUXNQ MXLJcoR2[2W|IHHwc5B1d3Orcx?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
RXF-631L MUjBdI91d3OrczDBd5NigQ>? MljONVAh|ryP NUnSeohrPDhiaB?= NF2xT45FVVOR NELyTFdKdmS3Y3XzJIFxd3C2b4Ppdy=> NFrzbHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
MKN-45 M2XBeGFxd3Sxc3nzJGF{e2G7 MnrhNVAh|ryP M4KyTlQ5KGh? MWTEUXNQ M1vBdGlv\HWlZYOgZZBweHSxc3nz Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
LNCaP MVnGeY5kfGmxbjDBd5NigQ>? M{DxZ|Eh|ryP NHzTS|lUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= M2fMPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO|k6Lz5{NUO2NFc6QTxxYU6=
LNCaP95 MmDDSpVv[3Srb36gRZN{[Xl? MlHaNUDPxE1? NEDJbmJUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= NYnUO2trRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlA4QTlpPkK1N|YxPzl7PD;hQi=>
A549 Ml3sSpVv[3Srb36gRZN{[Xl? M{nVPFUxOCCwTR?= NXnQUGFDPDhiaB?= NYToPVBPTE2VTx?= MYfJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? M2Prd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO|I6QTxxYU6=
A549 NUe5OHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPSNUDPxE1? MUO3NkBp NIXGSYZFVVOR NYj1OZF[UW6qaXLpeJMh[2WubDDndo94fGh? M4HGUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO|I6QTxxYU6=
H522 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXJWlgyKM7:TR?= M4jBXlczKGh? MU\EUXNQ M1yyb2lvcGmkaYTzJINmdGxiZ4Lve5Rp M3vxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO|I6QTxxYU6=
SKMES-1 NEPFSnVEgXSxdH;4bYMhSXO|YYm= NF3BbVYyKM7:TR?= NFzoeoQ4OiCq MnmyTY5lfWOnczDj[YxtKGSnYYTo NUDqUZRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
H596 M1fKemZ2dmO2aX;uJGF{e2G7 NX61PXl7OSEQvF2= NUXmZ|FZUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= NXnHTnpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCC2450 MWTGeY5kfGmxbjDBd5NigQ>? MV:xJO69VQ>? NIi1fYdKdXCjaYLzJINmdGxiaX72ZZNqd25? NVvVSZNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCT116 NFfZe2RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkmzO|IhcHK| NEfWV|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE41QCEQvF2u MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
MCF7 M4rK[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnzhO|IhcHK| MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFizszNMi=> NIjTbIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
U87MG M2\ib2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmL0O|IhcHK| MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLk[0JO69VS5? M4XENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
A549 NHz5OIlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVe3NkBpenN? MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwMEeg{txONg>? NYjCWHVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O|Y2QTB7PD;hQi=>
HeLa NHf3OHdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NEjiRlk4OiCqcoO= MljURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZVzhJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB2LkO0JO69VS5? NFG3bJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
HCT116 NWDPbWl3TnWwY4Tpc44h[XO|YYm= Moi4NVAhfU1? NYnlU3hDOSCqch?= NF;GXpBKdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JFExKHWPIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> NGPzXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma NFT6c3ZE\WyuIHP5Z4xmKGG|c3H5 MVe1JJVO MW[yOEBpenN? NWHn[3ptS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTJyNUigcYVt[W6xbXGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGP1ZmcyKHCqYYPlJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrcx?= MoniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
A2058 melanoma M2rpeGNmdGxiY4njcIUh[XO|YYm= MoXrOUB2VQ>? MYmyOEBpenN? MVXD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDBNlA2QCCvZXzhco9u[SClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDC1JJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> NGXsPJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyPVU6Oid-Mki4Nlk2QTJ:L3G+
SKOV3 NVjp[XNRS2WubDDjfYNt\SCjc4PhfS=> NWG0emN5OiC3TR?= NYq2cpZWOjRiaILz MkD3R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gV2tQXjNiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNkB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{ M4fNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
SKOV3 NW\1cXhbS2WubDDjfYNt\SCjc4PhfS=> NVXMSFdHOiC3TR?= MX2yOEBpenN? NVfzZZVDS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGP1ZmcyKHCqYYPlJIF1KDJidV2gZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrcx?= NEPwSIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyPVU6Oid-Mki4Nlk2QTJ:L3G+
MDA-MB-231 M4TBd2N6fG:2b4jpZ4l1gSCjc4PhfS=> MojkO|IhcHK| MniwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMT64PEDPxE1w NEPIUog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO|QzQSd-MkmxNFc1Ojl:L3G+
PC3 NFTrNnhEgXSxdH;4bYNqfHliYYPzZZk> NFnuR3g4OiCqcoO= NX3XN2FvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA2NjN2IN88UU4> MnnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
T47D NHzoVmREgXSxdH;4bYNqfHliYYPzZZk> NXnTXIxvPzJiaILz NU\KZmU{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPi57MjFOwG0v MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
MCF7 NGfMW|BEgXSxdH;4bYNqfHliYYPzZZk> MlftO|IhcHK| MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxNU4xPSEQvF2u MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
TC32 MmXKdWhVWyCjc4PhfS=> MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? M1XZS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MVzxTHRUKGG|c3H5 MlLadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? NED4U5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY M1PFfpFJXFNiYYPzZZk> MlnPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NX3j[nVUeUiWUzDhd5NigQ>? MnXtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= NVHQOXRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MoLXdWhVWyCjc4PhfS=> Ml22dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NY\YZ3QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MUHxTHRUKGG|c3H5 NInadYVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NW\STG8zeUiWUzDhd5NigQ>? NXzIPWF[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> M2HtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NV\5ZppEeUiWUzDhd5NigQ>? NXfnTIhjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NWDzSWJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) NGnuUVlyUFSVIHHzd4F6 MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MXjxTHRUKGG|c3H5 NVS5NW86eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> M3GwbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NUXFbXh6eUiWUzDhd5NigQ>? NGTER|NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MYnxTHRUKGG|c3H5 MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NUXXT5ZKeUiWUzDhd5NigQ>? MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NULHOJNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MorJdWhVWyCjc4PhfS=> MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> NH62S|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 M1XjRpFJXFNiYYPzZZk> NHzSdWtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= NEi2[5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MlrxdWhVWyCjc4PhfS=> MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=> NHvGU5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 M2K4T5FJXFNiYYPzZZk> M2DHdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> NFfrWXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS MYXxTHRUKGG|c3H5 M{DV[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>? NXX0NWFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NIPIb5ZyUFSVIHHzd4F6 MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz M3W0SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD Ml[4dWhVWyCjc4PhfS=> NHS2XZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 M3HWe5FJXFNiYYPzZZk> NF3XRndyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NG\2dos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC M{X3dZFJXFNiYYPzZZk> M1zSO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MVzxTHRUKGG|c3H5 M3vFbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NUHPO5BYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 Mkj5dWhVWyCjc4PhfS=> MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M1HIT5FJXFNiYYPzZZk> MmP6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NUT3VGVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NF25bFZyUFSVIHHzd4F6 NUnXOIU2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NXHjOJd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NXrBU4xSeUiWUzDhd5NigQ>? M1\sdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MkDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
insect MVnGeY5kfGmxbjDhd5NigQ>? M{D1WmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1PUtibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjBzMTFOwG0v MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|NE[wO{c,OzByM{S2NFc9N2F-
insect NEfaV4xHfW6ldHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEircz30ZYdo\WRicEi1ZYxxcGFxcEGxNIFteGijIFW1OFJMKG23dHHueEBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xOjlizszNMi=> NXH3XWhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21 MUfGeY5kfGmxbjDhd5NigQ>? NEDqd|QyKGi{ MYjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHytcIVv\3SqIF6teIVzdWmwYXygTIl{Pi22YXfn[YQheDFzMHTlcJRiN3KnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJIlve2WldDDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBu\WG|dYLl[EBi\nSncjCxJIhzKGK7IFHs[ZhiPjN|IGTyZYNmei2kYYPl[EBndHWxcnXzZ4Vv[2VicH;sZZItKEmFNUCgQUAxNjF{NTFOwG0v NWTQSJp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
MCF7 M2fs[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFG1RoM4OiCqcoO= M4PTVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDoZZJjd3KrbnegVGlMO0ODIFW1OFVMKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4zODZizszNMi=> NYWxbY1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21 M3XaVGZ2dmO2aX;uJIF{e2G7 MVexJIhz NU\sRoJ3UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtNWynbnf0bEBPNXSncn3pcoFtKEirc{[teIFo\2WmIICxNVBj\XSjL4LlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCSSWCyJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkAyKGi{IHL5JGFt\XijNkOzJHRz[WOncj3iZZNm\CCobIXvdoV{[2WwY3WgdI9t[XKrLDDJR|UxKD1iMD6yN|Qh|ryPLh?= MmSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
T47D M4HqSGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHnvOGc4OiCqcoO= MnvORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWNEfEJINmdGy|IHjhdoJwemmwZzDQTVNMS0FiSEGwOFdTKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4zQDZizszNMi=> M4DLcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5|MECzOFYxPzxxYU6=
PC3 NYm4eY1bTnWwY4Tpc44h[XO|YYm= NV7MdoFDOiCqcoO= M1fnfWlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KG2nYYP1doVlKGGodHXyJFIhcHK|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOzZ3IN88UU4> M3XaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5|MECzOFYxPzxxYU6=
HT-29 NYPLbmtRS2WubDDjfYNt\SCjc4PhfS=> MWiwMlEyOSC2bzCzJJVO NH7RS|IzPCCqcoO= M2nsXWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFAvOTFzIITvJFMhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? NHL4THo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECzOFYxPyd-M{CwN|Q3ODd:L3G+
A2058 NUTBOnhWTnWwY4Tpc44h[XO|YYm= MYCxJIhz MoDtTY5pcWKrdHnvckBw\iCWT2LDNkBqdiCqdX3hckBCOjB3ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDheEBU\XJ2N{OgZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYOsJGlEPTBiPTCwMlQyPiEQvF2u NEG5S|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO1PVAxOyd-M{CzOVkxODN:L3G+
A2058 M{LKU2Z2dmO2aX;uJIF{e2G7 NHPCOmcyKGi{ NVj6SoJOUW6qaXLpeIlwdiCxZjDUU3JEOSCrbjDoeY1idiCDMkC1PEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVNjDwbI9{eGixconsZZRqd25iYYSgV4VzOjN3L{KzOkBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPTV|IN88UU4> NWTSRnF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOVkxODNpPkOwN|U6ODB|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
- Collapse

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
- Collapse
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms NVP-BKM120
Smiles C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. December 12 2020 Phase 3
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02194049 Completed Drug: BKM120|Drug: cisplatin|Drug: etoposide Extensive Stage Small Cell Lung Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|Novartis July 2014 Phase 1
NCT02154776 Completed Drug: LEE011|Drug: Buparlisib|Drug: Letrozole Advanced or Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis June 27 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Buparlisib (BKM120) | Buparlisib (BKM120) supplier | purchase Buparlisib (BKM120) | Buparlisib (BKM120) cost | Buparlisib (BKM120) manufacturer | order Buparlisib (BKM120) | Buparlisib (BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID